I am a board-certified medical oncologist whose clinical practice is devoted to the care of patients with breast cancer, and I work as part of a multidisciplinary team to treat women with this disease. My research activities are focused on developing new therapeutic approaches for the treatment of breast cancer, and investigating the impact of these therapies on fertility and sexual health.
Currently, I am involved in clinical trials to evaluate anti-angiogenic agents, which are designed to cut off the tumor’s blood supply. In addition, I am investigating therapies that interfere with estrogen in women with hormone-receptor-positive breast cancer, and therapies that are targeted to other growth factor signaling pathways (e.g. the HER2 pathway). My colleagues and I are investigating these approaches when they are given alone or in combination (for example, giving both anti-estrogen therapy and anti-angiogenic therapy). I am also involved in clinical trials evaluating the effects of breast cancer therapy (e.g. chemotherapy) on ovarian reserve in premenopausal women, and the use of low dose intravaginal estrogen to ameliorate symptoms of vaginal dryness in postmenopausal women.
I am a member of a number of medical groups including the New York Metropolitan Breast Cancer Group, the American Society of Clinical Oncology (ASCO), and the American College of Physicians/American Society of Internal Medicine. I also serve on the National Cancer Institute-sponsored Cancer and Leukemia Group B (CALGB) Breast Committee, the ASCO Breast Cancer Education Committee, and the Endocrine-Related Cancer Journal Editorial Board.
I am an ad hoc reviewer for several clinical journals including The Lancet, the New England Journal of Medicine, Journal of Clinical Oncology, Clinical Cancer Research, and Breast Cancer Research and Treatment. I have written more than 20 peer-reviewed articles, review articles, and book chapters.
- Clinical Expertise: Breast Cancer
- Awards and Honors: New York Magazine Top Doctors (2005-2006; 2015-2016)
- Languages Spoken: English
- Education: MD, The University of Chicago Pritzker School of Medicine
- Residencies: The University of Chicago Hospitals
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Dickler M and Hudis CA. Aromatase Inhibitors for Treatment of Breast Cancer: From Metastatic Disease to Prevention. In: Principles and Practice of Oncology, Updates, 2003, 17:1-14.
Dickler MN, Contributing author, “Fulvestrant (Faslodex) for Advanced Breast Cancer,” Med Lett Drugs Ther 2002; 44:65-66.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Maura N. Dickler
- A Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- A Phase I Study of BYL719 with Letrozole or Exemestane for Treating Locally Advanced Inoperable or Metastatic Breast Cancer
- A Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- A Phase IB Study of Abemaciclib plus Hormonal Therapy in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- A Phase Ib/II Study of Ad-RTS-hIL-12 and Veledimex for Locally Advanced or Metastatic Breast Cancer
- A Phase II Study of Abemaciclib plus Trastuzumab versus Trastuzumab with Standard Chemotherapy in Patients with Advanced Breast Cancer
- Two Studies of GDC-0032: A Phase I Study of GDC-0032 for Solid Tumors with Increased PI3K Activity, and a Phase II Study of GDC-0032 with Fulvestrant in Patients with Advanced Breast Cancer
Clinical Trials Co-Investigated by Maura N. Dickler
- A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
- A Phase I Study of AZD9496 in Women with Estrogen Receptor-Positive HER2-Negative Breast Cancer
- A Phase I Study of LJM716, BYL719, and Trastuzumab in Women with Metastatic HER2-Positive Breast Cancer
- A Phase I Study of SGN-LIV1A in Women with Metastatic Breast Cancer
- A Phase I Study of the Immune Activity and Safety of IMC-CS4 in Patients with Advanced Breast or Prostate Cancers
- A Phase I/IB Study of LSZ102 Alone and with LEE011 or BYL719 in Patients with Metastatic Estrogen Receptor-Positive Breast Cancer
- A Phase IB Study of LEE011 and Exemestane with and without Everolimus in Women with Locally Advanced or Metastatic Breast Cancer
- A Phase III Study of Standard Hormonal Therapy Alone and with Palbociclib in Patients with Early-Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer
- A Phase III Study of Taselisib plus Fulvestrant versus Placebo plus Fulvestrant in Women with Recurrent or Metastatic HR-Positive HER2-Negative Breast Cancer
- A Study Assessing Fluorestradiol PET/CT for Imaging Estrogen Receptor Status
- A Study of Non-Hormonal Vaginal Moisturizer in Hormone Receptor-Positive Postmenopausal Cancer Survivors
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more